DK2683395T3 - Anvendelse af lav dosis il-2 til behandling af type 1-diabetes - Google Patents
Anvendelse af lav dosis il-2 til behandling af type 1-diabetes Download PDFInfo
- Publication number
- DK2683395T3 DK2683395T3 DK12708029.9T DK12708029T DK2683395T3 DK 2683395 T3 DK2683395 T3 DK 2683395T3 DK 12708029 T DK12708029 T DK 12708029T DK 2683395 T3 DK2683395 T3 DK 2683395T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- interleukin
- type
- dose
- diabetes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (17)
1. Interleukin-2 (IL-2) til anvendelse i behandling af type I-diabetes hos et menneskeligt individ, hvor IL-2 skal administreres i en dosis på mindre end 3,5 MIU/dag, hvor nævnte 11-2 er human IL-2 eller en aktiv analog deraf, hvilken aktiv analog har mindst 85 % aminosyreidentitet med human IL-2.
2. Interleukin-2 til anvendelse i behandling af type I-diabetes ifølge krav 1, hvor nævnte IL-2 er en aktiv analog af human IL-2, der har mindst 90 % aminosyreidentitet med human IL-2.
3. Interleukin-2 til anvendelse i behandling af type I-diabetes ifølge krav 2, hvor nævnte IL-2 er aldesleukin.
4. Interleukin-2 til anvendelse i behandling af type I-diabetes ifølge et hvilket som helst af kravene 1 til 3, hvor det skal administreres i en dosis på omkring 3 MIU/dag.
5. Interleukin-2 til anvendelse i behandling af type I-diabetes ifølge et hvilket som helst af kravene 1 til 3, hvor interleukin-2 (IL-2) skal administreres i en dosis på mindre end 2 MIU/dag.
6. Interleukin-2 til anvendelse i behandling af type I-diabetes ifølge et hvilket som helst af kravene 1 til 5, hvor IL-2 skal administreres gentagne gange.
7. Interleukin-2 til anvendelse i behandling af type I-diabetes ifølge et hvilket som helst af kravene 1 til 6, hvor behandlingen omfatter mindst et første forløb hvor interleukin-2 skal administreres en gang per dag over mindst 3 på hinanden følgende dage.
8. Interleukin-2 til anvendelse i behandling af type I-diabetes ifølge krav 7, hvor behandlingen omfatter mindst et første forløb hvor interleukin-2 skal administreres en gang per dag over 3 til 7 dage.
9. Interleukin-2 til anvendelse i behandling af type I-diabetes ifølge krav 7 eller 8, hvor nævnte første behandlingsforløb efterfølges af en vedligeholdelsesdosis efter 1 til 4 uger.
10. Interleukin-2 til anvendelse i behandling af type I-diabetes ifølge et hvilket som helst af kravene 1 til 9, hvor behandlingen er terapeutisk.
11. Interleukin-2 til anvendelse i behandling af type I-diabetes ifølge et hvilket som helst af kravene 1 til 9, hvor behandlingen er forebyggende.
12. Interleukin-2 til anvendelse i behandling af type I-diabetes ifølge et hvilket som helst af kravene 1 til 9, hvor behandlingen forebygger forekomst eller udvikling af type I-diabetes.
13. Interleukin-2 til anvendelse i behandling af eller forebyggelse af type I-diabetes ifølge krav 12, hvor individet har risiko for at udvikle type I-diabetes og behandlingen med IL-2 forbygger indtræden af diabetes hos nævnte individ.
14. Interleukin-2 til anvendelse i behandling af eller forebyggelse af type I-diabetes ifølge krav 13, hvor individet, som skal behandles, har en underproduktion af IL-2, og en restproduktion af insulin.
15. Interleukin-2 til anvendelse i behandling af type I-diabetes ifølge et hvilket som helst af kravene 1 til 14, hvor interleukin-2 skal administreres ved indsprøjtning eller ved oral, nasal eller topikal administrering.
16. Interleukin-2 til anvendelse i behandling af type I-diabetes ifølge et hvilket som helst af kravene 1 til 14, hvor interleukin-2 (IL-2) skal administreres ad subkutan vej.
17. Interleukin-2 til anvendelse i behandling af type I-diabetes ifølge et hvilket som helst af kravene 1 til 16, hvor interleukin-2 skal administreres i en farmaceutisk acceptabel bærer eller excipiens.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451663P | 2011-03-11 | 2011-03-11 | |
| EP11305269 | 2011-03-11 | ||
| PCT/EP2012/054174 WO2012123381A1 (en) | 2011-03-11 | 2012-03-09 | Use of low dose il-2 for treating autoimmune - related or inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2683395T3 true DK2683395T3 (da) | 2018-11-19 |
Family
ID=44244599
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12708029.9T DK2683395T3 (da) | 2011-03-11 | 2012-03-09 | Anvendelse af lav dosis il-2 til behandling af type 1-diabetes |
| DK18179669.9T DK3443979T3 (da) | 2011-03-11 | 2012-03-09 | Il-2-doseringsplan til behandling af systemisk lupus erythematosus |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18179669.9T DK3443979T3 (da) | 2011-03-11 | 2012-03-09 | Il-2-doseringsplan til behandling af systemisk lupus erythematosus |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12491232B2 (da) |
| EP (3) | EP3766513A1 (da) |
| JP (2) | JP6054889B2 (da) |
| KR (1) | KR102220006B1 (da) |
| CN (2) | CN109432407A (da) |
| AU (4) | AU2012228418B2 (da) |
| DK (2) | DK2683395T3 (da) |
| ES (1) | ES2693645T3 (da) |
| MX (2) | MX384095B (da) |
| PL (2) | PL3443979T3 (da) |
| WO (1) | WO2012123381A1 (da) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010206840B2 (en) | 2009-01-21 | 2015-02-05 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| US20140193410A1 (en) * | 2013-01-09 | 2014-07-10 | University Of Miami | Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein |
| EP3013355B1 (en) | 2013-06-25 | 2019-08-07 | ICM - Institut du Cerveau et da la Moelle Epinière | Il-2 for use in treating alzheimer disease and related disorders |
| PT3102595T (pt) | 2014-02-06 | 2019-01-11 | Hoffmann La Roche | Proteínas de fusão de interleucina-2 e suas utilizações |
| EP2918285A1 (en) * | 2014-03-11 | 2015-09-16 | Université Pierre et Marie Curie (Paris 6) | Interleukin-2 for treating food allergy |
| WO2015162124A1 (en) * | 2014-04-22 | 2015-10-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnostic of an autoimmune disease |
| CN104189892A (zh) * | 2014-08-22 | 2014-12-10 | 北京大学人民医院 | 低剂量白细胞介素2在免疫相关性疾病治疗中的应用 |
| WO2016057651A1 (en) | 2014-10-09 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Multiple-variable il-2 dose regimen for treating immune disorders |
| CN104459129A (zh) * | 2015-01-05 | 2015-03-25 | 复旦大学附属华山医院 | 一种鉴别活动性与潜伏性结核分枝杆菌感染的诊断试剂盒 |
| CR20170510A (es) | 2015-04-10 | 2018-02-26 | Amgen Inc | Muteínas de interuquina 2 para la expansión de células t regulatorias |
| EP3313429B1 (en) * | 2015-06-19 | 2021-10-06 | University Of Louisville Research Foundation, Inc. | Immunomodulation for the long term prevention and treatment of autoimmune diseases and foreign tissue rejection |
| US20190060407A1 (en) * | 2015-09-10 | 2019-02-28 | Assistance Publique - Hôpitaux De Paris | Use of interleukin 2 for treating spondyloarthritis |
| EP4406611A3 (en) * | 2016-01-11 | 2024-10-23 | Dignity Health | Modulators of zinc activated cation channel |
| JP6911044B2 (ja) * | 2016-03-16 | 2021-07-28 | シェ、ヤンホイＸｉｅ Ｙａｎｈｕｉ | 呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン２の組合せ |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| JP7271539B2 (ja) * | 2017-11-14 | 2023-05-11 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | リンホトキシンアルファ遺伝子について遺伝的に改変された調節性ｔ細胞及びその使用 |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| EP3752178A1 (en) | 2018-02-16 | 2020-12-23 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
| BR112020021564A2 (pt) * | 2018-05-21 | 2021-03-02 | Nektar Therapeutics | estimulador de treg seletivo rur20kd-il-2 e composições relacionadas |
| WO2020007937A1 (en) * | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
| EP3934680A4 (en) * | 2019-03-08 | 2022-12-07 | Cend Therapeutics, Inc. | LOW-DOSE CYTOKINE ADMINISTRATED WITH ANYTHING FOR THE TREATMENT OF CANCER |
| CN109999179A (zh) * | 2019-05-08 | 2019-07-12 | 山东省分析测试中心 | 低剂量白介素2用于制备治疗阿尔茨海默病药物中的应用 |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| CN110251659A (zh) * | 2019-07-03 | 2019-09-20 | 安徽省立医院 | 一种小剂量白细胞介素2在制备治疗慢性痛风药物中的应用 |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| PH12022550326A1 (en) | 2019-08-13 | 2023-03-13 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| JP7840267B2 (ja) | 2020-03-06 | 2026-04-03 | サントル、オスピタリエ、ユニヴェルシテール、ド、ニーム | 筋萎縮性側索硬化症の治療のための低用量ヒトインターロイキン－２ |
| US12098178B2 (en) | 2020-12-04 | 2024-09-24 | Visterra, Inc. | Methods of using interleukin-2 agents |
| US20240148827A1 (en) * | 2021-03-11 | 2024-05-09 | The Methodist Hospital | Methods and Compositions for Treatment of Disease |
| CN113304248B (zh) * | 2021-07-01 | 2023-01-03 | 北京大学人民医院 | Il-2在制备缓解糖皮质激素类药物副作用的药物中的应用 |
| CN115607653B (zh) * | 2022-07-09 | 2023-09-26 | 曹霞 | 低剂量白介素2在治疗孤独症中的应用 |
| CN115487292B (zh) * | 2022-09-28 | 2025-01-21 | 河北师范大学 | 一种治疗糖尿病的联合用药物及其应用 |
| EP4630035A1 (en) | 2022-12-05 | 2025-10-15 | Centre Hospitalier Universitaire de Nimes | Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients |
| CN115779072B (zh) * | 2023-02-06 | 2023-10-17 | 北京大学第三医院（北京大学第三临床医学院） | 一种包含低浓度il-2的用于治疗干眼的药物组合物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341562C (en) | 1982-03-31 | 2007-11-27 | Tadatsugu Taniguchi | Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell |
| IE56026B1 (en) | 1982-10-19 | 1991-03-27 | Cetus Corp | Cysteine-depleted muteins of biologically active proteins |
| WO1985000817A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
| US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
| US4530787A (en) | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
| US4656132A (en) | 1984-03-28 | 1987-04-07 | Cetus Corporation | Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria |
| US4752585A (en) | 1985-12-17 | 1988-06-21 | Cetus Corporation | Oxidation-resistant muteins |
| CA1340265C (en) | 1985-01-18 | 1998-12-15 | Kirston E. Koths | Oxidation resistant muteins |
| US4748234A (en) | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| JPS63183538A (ja) * | 1986-09-01 | 1988-07-28 | Takeda Chem Ind Ltd | 関節リウマチまたは全身性エリテマト−デスの改善，治療剤 |
| EP0262802A3 (en) * | 1986-09-01 | 1990-01-31 | Takeda Chemical Industries, Ltd. | Medicament for the treatment or improvement of rheumatoid arthritis or systemic lupus erythematosus |
| US5466447A (en) * | 1988-06-29 | 1995-11-14 | Amgen Inc. | Method for treating psoriasis |
| AU7578091A (en) | 1990-03-19 | 1991-10-21 | Brigham And Women's Hospital | Treatment of cachexia with interleukin 2 |
| FR2769505B1 (fr) | 1997-10-10 | 2000-06-30 | Michael Gerard Tovey | Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations |
| GB9724838D0 (en) | 1997-11-26 | 1998-01-21 | Franks Christopher R | Compositions |
| AU2002258606A1 (en) | 2001-03-30 | 2002-10-15 | Mayo Foundation For Medical Education And Research | Aerosol administration of interleukin-2 liposomes |
| NZ535549A (en) * | 2002-03-08 | 2006-02-24 | Monsanto Technology Llc | Treatment and prevention of inflammatory disorders |
| EP1426052B1 (en) * | 2002-12-02 | 2009-09-02 | Innate Pharma | Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof |
| GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| US20070098685A1 (en) | 2005-01-19 | 2007-05-03 | Brand Stephen J | Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist |
| JP2008528621A (ja) * | 2005-01-27 | 2008-07-31 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | 腎細胞ガンを処置するための方法 |
| EP2260057B1 (en) | 2008-03-13 | 2016-11-23 | Biotest AG | Anti-CD4 antibody dosage regimen for treating autoimmune disease |
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| WO2010049438A2 (en) * | 2008-10-30 | 2010-05-06 | Innate Pharma | Improved methods of using phosphoantigens for the treatment of diseases |
| AU2010206840B2 (en) | 2009-01-21 | 2015-02-05 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| CN102462837B (zh) * | 2010-11-19 | 2016-08-03 | 生物林格斯Ip有限公司 | 抗炎组合物 |
| BR112013023151A2 (pt) * | 2011-03-11 | 2020-09-15 | Assistance Publique - Hôpitaux De Paris | interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado |
-
2012
- 2012-03-09 DK DK12708029.9T patent/DK2683395T3/da active
- 2012-03-09 MX MX2017004594A patent/MX384095B/es unknown
- 2012-03-09 DK DK18179669.9T patent/DK3443979T3/da active
- 2012-03-09 EP EP20175639.2A patent/EP3766513A1/en active Pending
- 2012-03-09 WO PCT/EP2012/054174 patent/WO2012123381A1/en not_active Ceased
- 2012-03-09 PL PL18179669T patent/PL3443979T3/pl unknown
- 2012-03-09 MX MX2013010342A patent/MX347324B/es active IP Right Grant
- 2012-03-09 EP EP18179669.9A patent/EP3443979B1/en active Active
- 2012-03-09 KR KR1020137026950A patent/KR102220006B1/ko active Active
- 2012-03-09 PL PL12708029T patent/PL2683395T3/pl unknown
- 2012-03-09 AU AU2012228418A patent/AU2012228418B2/en active Active
- 2012-03-09 ES ES12708029.9T patent/ES2693645T3/es active Active
- 2012-03-09 JP JP2013557125A patent/JP6054889B2/ja active Active
- 2012-03-09 EP EP12708029.9A patent/EP2683395B1/en active Active
- 2012-03-09 CN CN201810358897.3A patent/CN109432407A/zh active Pending
- 2012-03-09 CN CN201280012853.6A patent/CN103732241A/zh active Pending
-
2016
- 2016-12-13 AU AU2016273847A patent/AU2016273847B2/en active Active
-
2018
- 2018-07-17 AU AU2018206705A patent/AU2018206705B2/en active Active
-
2020
- 2020-06-17 AU AU2020204023A patent/AU2020204023B2/en active Active
-
2023
- 2023-01-06 US US18/151,383 patent/US12491232B2/en active Active
- 2023-01-11 JP JP2023002251A patent/JP7561893B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12491232B2 (en) | Low dose IL-2 for treating autoimmune-related or inflammatory disorders | |
| US11559566B2 (en) | Use of low dose IL-2 for treating autoimmune-related or inflammatory disorders | |
| AU2009244039A1 (en) | Means for the treatment and/or prophylaxis of an autoimmune disease and for the formation of regulatory T-cells | |
| US20240335510A1 (en) | Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis | |
| HK40003184B (en) | Il-2 dosage regimen for treating systemic lupus erythematosus | |
| HK40003184A (en) | Il-2 dosage regimen for treating systemic lupus erythematosus | |
| CA2828657C (en) | Use of low dose il-2 for treating autoimmune - related or inflammatory disorders |